Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Intensity Allogeneic HSCT for Relapsed CNS Lymphoma
NCT02724904Phase 2Withdrawn
- Sponsor
- Massachusetts General Hospital
- Start
- May 2017
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of thiotepa in non-Hodgkin lymphoma (NHL), sponsored by Massachusetts General Hospital. Planned start May 2017; status: withdrawn.
02
Drugs
thiotepa
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02724904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02724904.